Free Trial

PureTech Health (LON:PRTC) Trading Up 14.2% - Still a Buy?

PureTech Health logo with Medical background

Key Points

  • PureTech Health's stock experienced a significant rise of 14.2%, closing at GBX 121.50 ($1.64) with a high of GBX 123.80 during trading.
  • The company's trading volume surged by 1,053%, with approximately 9 million shares changing hands compared to an average of around 781,000 shares.
  • Insider Bharatt Chowrira bought 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company's prospects, with insiders owning 13.13% of the stock.
  • Interested in PureTech Health? Here are five stocks we like better.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% during trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares traded hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 14.2%

The firm has a market capitalization of £293.65 million, a PE ratio of 714.71 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The business's fifty day moving average price is GBX 129.46 and its 200 day moving average price is GBX 129.76.

Insider Activity at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction dated Thursday, July 3rd. The stock was acquired at an average cost of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is currently owned by company insiders.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.